A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

NCT06516510 · clinicaltrials.gov ↗
EARLY_PHASE1
Phase
TERMINATED
Status
17
Enrollment
INDUSTRY
Sponsor class

Stopped Based on data from the Interim Analysis, the study will not adequately inform the clinical development programme for Lutetium (177Lu) rhPSMA-10.1 injection in the way that the study was intended. There are no concerns regarding participant safety.

Conditions

Interventions

Sponsor

Blue Earth Therapeutics Ltd

Collaborators